These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17643940)

  • 1. Hyperhomocysteinemia, inflammation and autoimmunity.
    Lazzerini PE; Capecchi PL; Selvi E; Lorenzini S; Bisogno S; Galeazzi M; Laghi Pasini F
    Autoimmun Rev; 2007 Aug; 6(7):503-9. PubMed ID: 17643940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?
    Lazzerini PE; Capecchi PL; Selvi E; Lorenzini S; Bisogno S; Galeazzi M; Laghi Pasini F
    Lupus; 2007; 16(11):852-62. PubMed ID: 17971357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
    Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
    Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia in acute iatrogenic hypothyroidism: the relevance of thyroid autoimmunity.
    Cicone F; Santaguida MG; My G; Mancuso G; Papa A; Persechino R; Virili C; Brusca N; Tofani A; Scopinaro F; Centanni M
    J Endocrinol Invest; 2018 Jul; 41(7):831-837. PubMed ID: 29288439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease.
    Jakubowski H
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 9():155-67. PubMed ID: 19261978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for telomerase activation in VSMCs exposed to hyperglycemic and hyperhomocysteinemic conditions.
    Jacob T; Hingorani A; Ascher E
    Angiology; 2009; 60(5):562-8. PubMed ID: 19398425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications.
    Erzin Y; Uzun H; Celik AF; Aydin S; Dirican A; Uzunismail H
    J Clin Gastroenterol; 2008; 42(5):481-6. PubMed ID: 18344891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease.
    Kerkeni M; Letaief A; Achour A; Miled A; Trivin F; Maaroufi K
    Clin Biochem; 2009 Jun; 42(9):777-82. PubMed ID: 19233152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS.
    Mikael LG; Rozen R
    Cardiovasc Res; 2008 Oct; 80(1):151-8. PubMed ID: 18540024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy.
    Vurucu S; Demirkaya E; Kul M; Unay B; Gul D; Akin R; Gokçay E
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):844-8. PubMed ID: 18234410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of hyperhomocysteinemia in chronic kidney disease.
    Massy ZA
    Semin Nephrol; 2006 Jan; 26(1):24-7. PubMed ID: 16412821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins.
    Apeland T; Frøyland ES; Kristensen O; Strandjord RE; Mansoor MA
    Epilepsy Res; 2008 Nov; 82(1):1-6. PubMed ID: 18644700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations].
    Herrmann W; Lorenzl S; Obeid R
    Fortschr Neurol Psychiatr; 2007 Sep; 75(9):515-27. PubMed ID: 17729191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
    Gisondi P; Girolomoni G
    Semin Thromb Hemost; 2009 Apr; 35(3):313-24. PubMed ID: 19452407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials.
    Antoniades C; Antonopoulos AS; Tousoulis D; Marinou K; Stefanadis C
    Eur Heart J; 2009 Jan; 30(1):6-15. PubMed ID: 19029125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular pathogenesis in hyperhomocysteinemia.
    Huang T; Yuan G; Zhang Z; Zou Z; Li D
    Asia Pac J Clin Nutr; 2008; 17(1):8-16. PubMed ID: 18364320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis.
    Hoţoleanu C; Porojan-Iuga M; Rusu ML; Andercou A
    Rom J Intern Med; 2007; 45(2):159-64. PubMed ID: 18333369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholestin (Monascus purpureus rice) inhibits homocysteine-induced reactive oxygen species generation, nuclear factor-kappaB activation, and vascular cell adhesion molecule-1 expression in human aortic endothelial cells.
    Lin CP; Chen YH; Chen JW; Leu HB; Liu TZ; Liu PL; Huang SL
    J Biomed Sci; 2008 Mar; 15(2):183-96. PubMed ID: 17906965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of homocysteine toxicity in humans.
    Perła-Kaján J; Twardowski T; Jakubowski H
    Amino Acids; 2007; 32(4):561-72. PubMed ID: 17285228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhomocysteinemia--the biochemical link between a weak heart and brittle bones?
    Herrmann M; Taban-Shomal O; Müller S; Gunter L; Hübner U; Böhm M; Herrmann W
    Clin Lab; 2006; 52(3-4):137-47. PubMed ID: 16584060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.